
    
      OBJECTIVES:

        -  Determine the 1-year recurrence-free survival rate of patients with stage 0 or I
           recurrent transitional cell carcinoma of the bladder treated with tipifarnib.

      OUTLINE: This is a multicenter study.

      Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days
      for up to 12 courses in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study within 18 months.
    
  